Ultragenyx Pharmaceutical
RARE
295 hedge funds and large institutions have $2.05B invested in Ultragenyx Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 125 increasing their positions, 83 reducing their positions, and 48 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
51% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 83
29% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 48
4.16% more ownership
Funds ownership: 97.37% → 101.53% (+4.2%)
3% more funds holding
Funds holding: 287 → 295 (+8)
8% more call options, than puts
Call options by funds: $27.9M | Put options by funds: $25.8M
5% less capital invested
Capital invested by funds: $2.16B → $2.05B (-$108M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.5M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$69M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$53.5M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$46.3M |
| 5 |
Two Sigma Investments
New York
|
+$40.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$84M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$63.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.6M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$46.4M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
-$33.4M |
RARE Hedge Fund Activity: Q1 2026 in Review
295 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2026, worth a combined $2.05B — down 5% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new RARE positions and 48 closed out — a net gain of 14 holders — while 125 added to existing stakes and 83 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $72.5M. The largest seller was JP Morgan Chase, cutting an estimated $84M.
- 295 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2026, up from 287 in Q4 2025.
- Funds reported $2.05B of Ultragenyx Pharmaceutical stock for Q1 2026, down 5% quarter-over-quarter.
- 62 funds opened new Ultragenyx Pharmaceutical positions in Q1 2026 and 48 closed out, a net change of +14 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2026 was AQR Capital Management, an estimated $72.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2026 was JP Morgan Chase, an estimated $84M sold.
Based on aggregated 13F filings for Q1 2026.